RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that it is
offering to sell, subject to market and other conditions, shares of its
common stock pursuant to an effective shelf registration statement in an
underwritten public offering for a total of no more than $20 million in
gross proceeds. As part of this offering, BioCryst intends to grant the
underwriters a 30-day option to purchase shares of common stock. All of
the shares to be sold in the offering are being sold by BioCryst, with
the proceeds to be used for general corporate purposes, including
funding clinical development of BCX4161,
continued development of second generation hereditary angioedema
compounds and pre-commercialization activities relating to intravenous peramivir.
Wells Fargo Securities, LLC and JMP Securities LLC are acting as joint
book-running managers, with Noble Financial Capital Markets acting as
co-manager for the proposed offering. The offering is expected to price
on July 31, 2013.
A shelf registration statement relating to the shares of common stock
described above has been previously filed with and declared effective by
the U.S. Securities and Exchange Commission. This press release does not
constitute an offer to sell, or the solicitation of an offer to buy,
these securities, nor will there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or sale is
not permitted. Any offer, if at all, will be made only by means of a
prospectus, including a preliminary prospectus supplement, forming part
of the effective shelf registration statement.
A preliminary prospectus supplement relating to the offering will be
filed with the SEC and will be available on its web site at www.sec.gov.
Copies of the preliminary prospectus supplement and accompanying
prospectus may be obtained from Wells Fargo Securities, LLC, 1525 West
W.T. Harris Boulevard, NC0675, Charlotte, NC 28262, Attn: Capital
Markets Client Support, telephone: 1-800-326-5897 or email: cmclientsupport@wellsfargo.com;
or JMP Securities LLC, Attn: Prospectus Department, 600 Montgomery
Street, 10th Floor, San Francisco, CA 94111, telephone: 1-415-835-8985.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small
molecule drugs that block key enzymes involved in infectious and
inflammatory diseases, with the goal of addressing unmet medical needs
of patients and physicians. BioCryst currently has two late-stage
development programs: peramivir, a viral neuraminidase inhibitor for the
treatment of influenza, and ulodesine,
a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of
gout. In addition, BioCryst has several early-stage programs: BCX4161
and a next generation oral inhibitor of plasma kallikrein for hereditary
angioedema and BCX4430,
a broad spectrum antiviral for hemorrhagic fevers. For more information,
please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
BioCryst Pharmaceuticals
Investors & Media:
Robert
Bennett, 919-859-7910
Source: BioCryst Pharmaceuticals, Inc.
News Provided by Acquire Media